Natalie Nanayakkara

Natalie Nanayakkara

Auto-generated profile, based on publicly available information

Natalie Nanayakkara

Baker Heart and Diabetes Institute Melbourne VIC

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
NNNatalie Nanayakkara
Natalie Nanayakkara
ACAndrea Curtis
Andrea Curtis
SHstephane heritier
stephane heritier
AGAdelle Gadowski
Adelle Gadowski
MPMeda E. Pavkov
Meda E. Pavkov
SZSophia Zoungas
Sophia Zoungas
Aims/hypothesis: Few studies examine the association between age at diagnosis and subsequent complications from type 2 diabetes. This paper aims to summarise the risk of mortality, macrovascular complications and microvascular complications associated with age at diagnosis of type 2 diabetes. Methods: Data were sourced from MEDLINE and All EBM (Evidence Based Medicine) databases from inception to July 2018. Observational studies, investigating the effect of age at diabetes diagnosis on macrovascular and microvascular diabetes complications in adults with type 2 diabetes were selected according to pre-specified criteria. Two investigators independently extracted data and evaluated all studies. If data were not reported in a comparable format, data were obtained from authors, presented as minimally adjusted ORs (and 95% CIs) per 1 year increase in age at diabetes diagnosis, adjusted for current age for each outcome of interest. The study protocol was recorded with PROSPERO International Prospective Register of Systematic Reviews (CRD42016043593). Results: Data from 26 observational studies comprising 1,325,493 individuals from 30 countries were included. Random-effects meta-analyses with inverse variance weighting were used to obtain the pooled ORs. Age at diabetes diagnosis was inversely associated with risk of all-cause mortality and macrovascular and microvascular disease (all p < 0.001). Each 1 year increase in age at diabetes diagnosis was associated with a 4%, 3% and 5% decreased risk of all-cause mortality, macrovascular disease and microvascular disease, respectively, adjusted for current age. The effects were consistent for the individual components of the composite outcomes (all p < 0.001). Conclusions/interpretation: Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality.

1 March 2018 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
NNNatalie Nanayakkara
Natalie Nanayakkara
SRSanjeeva Ranasinha
Sanjeeva Ranasinha
AGAdelle Gadowski
Adelle Gadowski
SHStephane Heritier
Stephane Heritier
JFJeff R. Flack
Jeff R. Flack
SZSophia Zoungas
Sophia Zoungas

1 June 2018 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
NNN. Nanayakkara
N. Nanayakkara
APA. J. Pease
A. J. Pease
SRS. Ranasinha
S. Ranasinha
NWN. Wischer
N. Wischer
SAS. Andrikopoulos
S. Andrikopoulos
SZSophia Zoungas
Sophia Zoungas

7 February 2016 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
AJAnju Joham
Anju Joham
NNNatalie Nanayakkara
Natalie Nanayakkara
SRSanjeeva Ranasinha
Sanjeeva Ranasinha
SZSophia Zoungas
Sophia Zoungas
JBJacqueline A. Boyle
Jacqueline A. Boyle
HTHelena Jane Teede
Helena Jane Teede

2 June 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
APAnthony Pease
Anthony Pease
Arul EarnestArul Earnest
Arul Earnest
SRSanjeeva Ranasinha
Sanjeeva Ranasinha
NNNatalie Nanayakkara
Natalie Nanayakkara
DLDanny Liew
Danny Liew
SZSophia Zoungas
Sophia Zoungas
Cardiovascular risk stratification is complex in type 1 diabetes. We hypothesised that traditional and diabetes-specific cardiovascular risk factors were prevalent and strongly associated with cardiovascular disease (CVD) among adults with type 1 diabetes attending Australian diabetes centres. De-identified, prospectively collected data from patients with type 1 diabetes aged ≥ 18 years in the 2015 Australian National Diabetes Audit were analysed. The burden of cardiovascular risk factors [age, sex, diabetes duration, glycated haemoglobin (HbA1c), blood pressure, lipid profile, body mass index, smoking status, retinopathy, renal function and albuminuria] and associations with CVD inclusive of stroke, myocardial infarction, coronary artery bypass graft surgery/angioplasty and peripheral vascular disease were assessed. Restricted cubic splines assessed for non-linearity of diabetes duration and likelihood ratio test assessed for interactions between age, diabetes duration, centre type and cardiovascular outcomes of interest. Discriminatory ability of multivariable models were assessed with area under the receiver operating characteristic (ROC) curves. Data from 1169 patients were analysed. Mean (± SD) age and median diabetes duration was 40.0 (± 16.7) and 16.0 (8.0–27.0) years respectively. Cardiovascular risk factors were prevalent including hypertension (21.9%), dyslipidaemia (89.4%), overweight/obesity (56.4%), ever smoking (38.5%), albuminuria (31.1%), estimated glomerular filtration rate < 60 mL/min/1.73 m2 (10.3%) and HbA1c > 7.0% (53 mmol/mol) (81.0%). Older age, longer diabetes duration, smoking and antihypertensive therapy use were positively associated with CVD, while high density lipoprotein-cholesterol and diastolic blood pressure were negatively associated (p < 0.05). Association with CVD and diabetes duration remained constant until 20 years when a linear increase was noted. Longer diabetes duration also had the highest population attributable risk of 6.5% (95% CI 1.4, 11.6). Further, the models for CVD demonstrated good discriminatory ability (area under the ROC curve 0.88; 95% CI 0.84, 0.92). Cardiovascular risk factors were prevalent and strongly associated with CVD among adults with type 1 diabetes attending Australian diabetes centres. Given the approximate J-shaped association between type 1 diabetes duration and CVD, the impact of cardiovascular risk stratification and management before and after 20 years duration needs to be further assessed longitudinally. Diabetes specific cardiovascular risk stratification tools incorporating diabetes duration should be an important consideration in future guideline development.

17 August 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
NNNatalie Nanayakkara
Natalie Nanayakkara
SRSanjeeva Ranasinha
Sanjeeva Ranasinha
AGAdelle Gadowski
Adelle Gadowski
WDWendy Davis
Wendy Davis
JFJeffrey Ronald Flack
Jeffrey Ronald Flack
SZSophia Zoungas
Sophia Zoungas
Objective To compare the glycaemic control and cardiovascular risk factor profiles of younger and older patients with type 2 diabetes. Cross-sectional analysis of data from the 2015 Australian National Diabetes Audit was undertaken. Methods Data were obtained from adults with type 2 diabetes presenting to Australian secondary/tertiary diabetes centres. Logistic regression examined associations with glycated haemoglobin A1c (HbA1c) >7% (53 mmol/mol) and cardiovascular risk factors. Results Data from 3492 patients were analysed. Mean (±SD) age was 62.9±12.5 years, mean diabetes duration 13.5±9.4 years and mean HbA1c 8.2%±1.8%. Mean HbA1c was 8.6%±2.1% and 8.0%±1.6% for the younger (<60 years) and older subgroups (≥60 years), respectively (p7.0% was 1.5 times higher (95% CI 1.22 to 1.84) for younger patients compared with older patients after adjustment for gender, smoking, diabetes duration, renal function and body mass index. Younger patients were also more likely to have dyslipidaemia (aOR 2.02, 95% CI 1.53 to 2.68; p<0.001), be obese (aOR 1.25, 95% CI 1.05 to 1.49; p<0.001) and be current smokers (aOR 2.13 95% CI 1.64 to 2.77; p<0.001) than older patients. Conclusions Younger age was associated with poorer glycaemic control and adverse cardiovascular risk factor profiles. It is imperative to optimise and monitor treatment in order to improve long-term outcomes.